Company news

XOMA Royalty Corporation news in 2025

XOMA Royalty Corporation's news releases, calls and decks from 2025, newest first.

View company

XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab

December 30, 2025

XOMA Royalty Declares Quarterly Preferred Stock Dividends

December 22, 2025

XOMA Royalty Enters into Agreement to Acquire Generation Bio

December 15, 2025

XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

December 5, 2025

Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty

November 26, 2025

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

November 21, 2025

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

November 12, 2025

Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty

October 24, 2025

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

October 17, 2025

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

October 2, 2025

ESSA Pharma Inc. Amends Agreement with XenoTherapeutics

September 24, 2025

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

September 17, 2025

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

September 3, 2025

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

August 20, 2025

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

August 13, 2025

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

August 11, 2025

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

August 4, 2025

HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

August 4, 2025

ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction

July 14, 2025

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

June 27, 2025

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

May 27, 2025

XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements

May 13, 2025

XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

May 7, 2025

XOMA Royalty Completes Sale of Kinnate Pipeline Assets

April 14, 2025

XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference

April 2, 2025

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

March 17, 2025

XOMA Royalty to Present at Investor Conferences in March

February 24, 2025

Decks in 2025